

Synthesis of Novel Levamisole Derivatives for Their Anticancer and Antiviral Activity

Sujith*, Chudamani B and Subhas S Karki

Department of Chemistry and Toxicology, AIIMS Delhi, New Delhi, India

Abstract

All the compounds (CH-69 to CH-84) were evaluated for their cytostatic activity against human HeLa cervix carcinoma cells, human CEM CD4⁺ T-lymphocytes as well as murine L1210 cells. All assays were performed in 96 well microtiter plates. To each well were added (5-7.5) × 10⁴ tumor cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37°C in a humidified CO₂ controlled atmosphere. At the end of the incubation period, the cells were counted in a coulter counter. The IC₅₀ (50% inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50%. The cytotoxicity and antiviral activity of a new series of 2-arylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-one against different MDCK cell cultures, HeLa cell cultures, vero cell cultures, CRFK cell cultures is reported. Among the tested compounds, inhibitory effects of compounds (CH-69 to CH-84) on the proliferation of murine leukemia cells (L1210) and human T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa).

Keywords: HeLa • MDCK • CRFK • Thymidine kinase-deficient (TK-) HSV-1 Kos strain • Herpes simplex virus

Introduction

Levamisole was introduced by Janssen pharmaceuticals in 1966 as anthelmintic agent to treat worm infestations in both humans and animals [1]. Later it was withdrawn from the market because of the serious side effects like agranulocytosis [2]. After being pulled out, the molecule has been tested in combination with fluorouracil to treat colon cancer. Evidence from clinical trials supports its addition to fluorouracil therapy to benefit patients with colon cancer [3]. Chemically levamisole is imidazothiazole derivative. Like levamisole, the modified molecule "Imidazo [2,1-b][1,3,4]thiadiazole" also bears anticancer property (Figure 1).




Figure 1. Synthesis of target molecule from levamisole.

There are two types of bicyclic imidazo [2,1-b]-1,3,4-thiadiazole ring systems are possible. Both the ring systems have nitrogen as a bridgehead atom at 4th position. It is pseudo aromatic in nature containing imidazole as electron rich centre and desired substitution can be done at 2nd, 5th and 6th position by starting with appropriate synthons (Figure 2).



Figure 2. Imidazo [2,1-b]-1,3,4-thiadiazole and Imidazo [5,1-b]-1,3,4-thiadiazole.

Other researchers have shown imidazo[2,1-b][1,3,4]thiadiazole nucleus as a useful scaffold for the development of novel anticancer agent [4-8].

Based on above discussion, 2-naphthyl-6-aryl-imidazo[2,1-b][1,3,4]thiadiazole nucleus has been taken as the target molecule for the thesis entitled "synthesis of levamisole derivatives for anti-cancer activity".

*Address for Correspondence: Sujith, Department of Chemistry and Toxicology, AIIMS Delhi, New Delhi, India, Tel: 9480774708; E-mail: ammumani1@gmail.com

Copyright: © 2022 Sujith, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.


Received: 11 July, 2022, Manuscript No. CSJ-22-69043; Editor assigned: 14 July, 2022, PreQC No. CSJ-22-69043 (PQ); Reviewed: 29 July, 2022, QC No. CSJ-22-69043; Revised: 09 September, 2022, Manuscript No. CSJ-22-69043 (R); Published: 17 September, 2022, DOI: 10.37421/2150-3494.2022.13.304

Methods and Materials

All chemicals procured for the proposed research work is of high purity. Purity of all chemicals to be confirmed by TLC and solvents to be used after distillation. Proposed research work is comprised of following steps:

1) General method of synthesis of 2-amino-5-substituted-1,3,4-thiadiazole

0.034 M of Phosphorous oxychloride was added drop-wise to mixture of 0.01 M of carboxylic acid [E] and thiosemicarbazide [F] with constant stirring. The reaction mixture was refluxed for one hour, cooled and added to 250 ml of ice-cold water and neutralized with 10% potassium hydroxide solution. The precipitate of 2-amino-5-substituted-1,3,4-thiadiazole [G] was filtered, washed with water and crystallized from DMF-ethanol mixture.




2-amino-5-substituted-1,3,4-thiadiazole

2) General method of synthesis of 3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

Equimolar quantity of 3-(2-bromoacetyl)-2H-chromen-2-one [D] and 5-substituted-1,3,4-thiadiazole-2-amine [G] in ethanol was refluxed for 10 hours-12 hours. The reaction mixture was poured in ice-cold water and pH of the solution was adjusted to 7.0 with aqueous solution of Na_2CO_3 to get 3-(2-substituted imidazo [2,1-


b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one. The compound so obtained was purified from chloroform-ethanol mixture.



3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

3) General method of synthesis of 5-bromo-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

To a well stirred mixture of 0.0050 M of anhydrous sodium acetate and 0.0025 M of an appropriate 3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one, 0.0025 M of bromine was added drop wise at room temperature. The stirring was stirred for 1 hour and later poured into ice cold water. The separated solid was filtered and recrystallized from chloroform-ethanol mixture. Physical constant values are given in Table 1.



5-bromo-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one:



Code	R	Nature	% Yield	M.P (°C)	M.F	M.W	R _f Value
CH-69		Yellow, amorphous	62	210-212	$\text{C}_{22}\text{H}_{17}\text{N}_3\text{O}_5\text{S}$	435.45	0.56
CH-70	2-Methyl thiophene	Brown, crystalline	40	196-98	$\text{C}_{18}\text{H}_{11}\text{N}_3\text{O}_2\text{S}_2$	365.43	0.54
CH-71	0	Brown, amorphous	68	222-224	$\text{C}_{14}\text{H}_9\text{N}_3\text{O}_2\text{S}$	283.3	0.52
CH-72	Phenyl	White, amorphous	65	278-80	$\text{C}_{19}\text{H}_{11}\text{N}_3\text{O}_2\text{S}$	345.37	0.5
CH-73	Thiophene	Brown, crystalline	70	290-292	$\text{C}_{17}\text{H}_9\text{N}_3\text{O}_2\text{S}_2$	351.4	0.77


Table 1. Physical parameters of different 5-bromo-3-(2-substituted imidazo [2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one.



5-bromo-3-(2-substituted imidazo [2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

4) General method of synthesis of 5-thiocyanato-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one


0.0025 M of bromine in glacial acetic acid (10 ml) was added drop wise at 0°C to a solution of 0.0025 M of 3-(2-substituted imidazo[2,1-



5-thiocyanato-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

Code	R	Nature	% Yield	M.P (°C)	M.F	M.W	R _f
CH-74		Yellow, amorphous	55	218-220	C ₂₂ H ₁₈ BrN ₃ O ₅ S	514.35	0.63
CH-75	-CH ₃	White, amorphous	50	199-200	C ₁₄ H ₈ BrN ₃ O ₂ S	362.2	0.55
CH-76	Thiophene	Brown, amorphous	60	248-249	C ₁₇ H ₈ BrN ₃ O ₂ S ₂	430.29	0.48


Table 2. Physical parameters of different 5-thiocyanato-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one.




5-thiocyanato-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

5) General method of synthesis of 5-formyl-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one

0.002 M of 3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one was added to the freshly prepared Vilsmeier-Haack Reagent (prepared by the adding 0.75 ml of POCl₃ drop wise to 5 ml of DMF at 0°C-5°C for 30 min) at room temperature. Stirring was continued for 4 hours at 80°C-90°C. The resulting reaction mixture was poured into ice cold water and neutralized to pH 7 with cold aqueous solution of sodium carbonate (Figures 3 and 4). The solid so obtained was filtered and recrystallized from ethanol (Tables 3-6).



5-formyl-3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one



3-(2-substituted imidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-ones



Code	R	Nature	% Yield	M.P (°C)	M.F	M.W	R _f
CH-77		Yellow, amorphous	70	242-244	C ₂₃ H ₁₆ N ₄ O ₅ S ₂	492.53	0.44
CH-78		White, amorphous	55	180-182	C ₂₄ H ₁₈ N ₄ O ₅ S ₂	506.55	0.56

Table 3. Physical parameters of different 5-formyl-3-(2-substituted imidazo [2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one.



5-formyl-3-(2-substituted imidazo [2,1-b]-1,3,4-thiadiazol-6-yl)-2H-chromen-2-one



Code	R	Nature	% Yield	M.P (°C)	M.F	M.W	R _f Value
CH-79		Light, yellow	35	192-194	C ₂₃ H ₁₇ N ₃ O ₆ S	463.46	0.54
CH-80		White, amorphous	40	178-180	C ₂₄ H ₁₉ N ₃ O ₆ S	477.49	0.66
CH-81	Phenyl	Brown, amorphous	45	250-252	C ₂₀ H ₁₁ N ₃ O ₃ S	373.38	0.72
CH-82	Thiophene	Brown, crystalline	40	278-280	C ₁₈ H ₉ N ₃ O ₃ S ₂	379.41	0.58

Table 4. IR Spectral data of synthesized derivatives.

Compound code	Spectral peaks (cm ⁻¹)	Molecular stretch
CH-69	3050.01, 2972.73-2734	C-H (aromatic)
	1724.05, 1590.99	C-H (aliphatic)
	1476.24	>C=O
		>C=N
CH-70		>C=C
	3034.44	C-H (aromatic)
	2968.87-2911.99	-C-H (aliphatic)
	1716.34	>C=O (Ketone)
	1605.45	>C=N
	1480.1	>C=C

CH-71	3042.16	-C-H (aromatic)
	2899.45-2844.49	-C-H (aliphatic)
	1722.12	>C=O (Ketone)
	1609.31	>C=N
	1462.74	>C=C
CH-72	3046.98	-C-H (aromatic)
	2972.73	-C-H (aromatic)
	1718.26	>C=O
	1606.41	>C=N
	1432.85	>C=C
CH-73	3058.55	-C-H (aromatic)
	2966.95-2826.17	-C-H (aliphatic)
	1713.44	>C=O (Ketone)
	1606.41	>C=N
	1471.42	>C=C
CH-74	2997.8	C-H (aromatic)
	2942.84-2826.17	C-H (aliphatic)
	1738.51	>C=O
	1610.27	>C=N
	1478.17	>C=C
CH-75	3045.05	-C-H (aromatic)
	2924.52-2961.16	-C-H (aliphatic)
	1729.83	>C=O (Ketone)
	1604.48	>C=N
	1471.42	>C=C
CH-76	3052.76	-C-H (aromatic)
	2942.84-2765.42	-C-H (aliphatic)
	1729.83	>C=O (Ketone)
	1597.41	>C=N
	1471.42	>C=C
CH-77	3028.66	C-H (aromatic)
	2979.48-2833.48	C-H (aliphatic)
	2167.6	-CN
	1707.66	>C=O
	1610.27	>C=N
	1466.6	>C=C
CH-78	2942.84-2747.10	-C-H (aliphatic)
	2158.92	-CN
	1702.84	>C=O

	1604.48	>C=N
	1465.83	>C=C
CH-79	2942.84-2836.77	-C-H (aliphatic)
	1721.16	>C=O (Ketone)
	1677.77	>C=O (Aldehyde)
	1589.06	>C=N
	1474.31	>C=C
CH-80	3001.2	-C-H (aromatic)
	2906.20-2747.10	-C-H (aliphatic)
	1716.34	>C=O (Ketone)
	1654.62	>C=O (Aldehyde)
	1598.7	>C=N
	1467.56	>C=C
CH-82	3061.44	-C-H (aromatic)
	2972.73-2869.56	-C-H (aliphatic)
	1712.48	>C=O (Ketone)
	1664.27	>C=O (Aldehyde)
	1610.27	>C=N
	1475.28	>C=C

Table 5. ¹H NMR spectral data of synthesized compounds.

Compound code	Chemical shift value (δ) in ppm and proton nature
CH-69	8.68 (1H, s, ar.), 8.60 (1H, s, ar.), 7.88-7.85 (1H, m, ar.), 7.67-7.57 (1H, m, ar.), 7.45 (1H, d, J=8), 7.37 (1H, t, J=16), 7.17 (2H, s, ar.), 3.89 (6H, s, 2-OCH ₃), 3.75 (3H, s, -OCH ₃).
CH-70	8.67 (1H, s, ar.), 8.58 (1H, s, ar.), 7.88-7.86 (1H, m, ar.), 7.63-7.59 (1H, m, ar.), 7.52-7.50 (1H, d, ar.), 7.47 (1H, d, J=8), 7.38 (1H, t, J=16), 7.16-7.15 (1H, m, ar.), 4.73 (2H, s, -CH ₂).
CH-71	8.64 (1H, s, ar.), 8.52 (1H, s, ar.), 7.87-7.85 (1H, m, ar.), 7.62-7.58 (1H, m, ar.), 7.46 (1H, d, J=8), 7.38 (1H, t, J=16), 2.74 (3H, s, -CH ₃).
CH-72	8.72 (1H, s, ar.), 8.68 (1H, s, ar.), 7.99 (2H, d, J=8), 7.91 (1H, d, J=8), 7.65-7.59 (4H, m, ar.), 7.49 (1H, d, J=8), 7.40 (1, t, J=16).
CH-73	10.03 (1H, s, -CHO), 8.57 (1H, s, ar.), 8.01-7.97 (3H, m, ar.), 7.92-7.89 (1H, m, ar.), 7.73-7.69 (2H, m, J=16), 7.52 (1H, d, J=8), 7.43 (1H, t, J=16), 7.32-7.30 (1H, m, ar.)
CH-74	8.39 (1H, s, ar.), 7.87-7.85 (1H, m, ar.), 7.70-7.65 (1H, m, ar.), 7.49 (1H, d, J=8), 7.41 (1H, t, J=16), 7.21 (2H, s, ar.), 3.92 (6H, s, 2-OCH ₃), 3.77 (3H, s, -OCH ₃).
CH-75	8.33 (1H, s, ar.), 7.85-7.82 (1H, m, ar.), 7.68-7.64 (1H, m, ar.), 7.47 (1H, d, J=8), 7.40 (1H, t, J=16), 2.78 (3H, s, -CH ₃).
CH-76	8.70 (1H, s, -ar.), 8.63 (1H, s, ar.), 7.97-7.95 (1H, m, ar.), 7.90-7.88 (2H, m, ar.), 7.64-7.60 (1H, m, ar.), 7.48 (1H, d, J=8), 7.40 (1H, t, J=16), 7.30-7.28 (1H, m, ar.)
CH-77	8.55 (1H, s, ar.), 7.92-7.90 (1H, m, ar.), 7.73-7.69 (1H, m, ar.), 7.53 (1H, d, J=8), 7.44 (1H, t, J=16), 7.26 (2H, s, ar.), 3.93 (6H, s, 2-OCH ₃), 3.78 (3H, s, -OCH ₃).
CH-78	8.47 (1H, s, ar.), 7.89 (1H, d, J=8), 7.69 (1H, t, J=16), 7.51 (1H, d, J=8), 7.42 (1H, t, J=16), 6.79 (2H, s, ar.), 4.49 (2H, s, -CH ₂), 3.77 (6H, s, 2-OCH ₃), 3.65 (3H, s, -OCH ₃).

CH-79	10.07 (1H, s, -CHO), 8.59 (1H, s, ar.), 7.92 (1H, d, j=8), 7.71 (1H, t, J=16), 7.52 (1H, d, J=8), 7.43 (1H, t, j=16), 7.25 (2H, s, ar.), 3.93 (6H, s, -OCH ₃), 3.77 (6H, s, -OCH ₃).
CH-80	10.05 (1H, s, -CHO), 8.52 (1H, s, ar.), 7.90 (1H, d, j=8), 7.70 (1H, t, j=16), 7.50 (1H, d, j=8), 7.42 (1H, t, j=16), 6.78 (2H, s, ar.), 4.47 (2H, s, -CH ₂), 3.77 (6H, s, 2-OCH ₃), 3.65 (3H, s, -OCH ₃).
CH-82	8.37 (1H, s, -ar.), 8.00-7.99 (1H, m, ar.), 7.94-7.93 (1H, m, ar.), 7.87-7.84 (1H, m, ar.), 7.69-7.65 (1H, m, ar.), 7.48 (1H, d, j=8), 7.43-7.38 (1H, m, ar.), 7.31-7.29 (1H, m, ar.)

Table 6. Compound code and chemical shift value (δ) in ppm and proton nature.




Figure 3. IR spectra of 3-(2-(3,4,5-trimethoxyphenyl)imidazo [2,1-b] [1,3,4] thiazol-6-yl)-2H-chromen-2-one. [CH₆₉].




Figure 4. ¹H-NMR spectra of 3-(2-(3,4,5-trimethoxyphenyl)imidazo [2,1-b] [1,3,4] thiazol-6-yl)-2H-chromen-2-one. [CH₆₉].

Results and Discussion

2-aryl-6-aryl-imidazo-[2,1-b][1,3,4]-thiadiazoles

Series of 2,6-disubstituted-imidazothiadiazoles were prepared. The FTIR spectra find peaks in the range of 3125-3008 and 2969 cm⁻¹-2764 cm⁻¹ for aromatic and aliphatic -CH respectively. The imine (-C=N) and -C=C (Ar.) stretching observed between 1621 cm⁻¹-1563 cm⁻¹ and 1545 cm⁻¹-1463 cm⁻¹ respectively. Presence of -C=O stretching at 1702 cm⁻¹ and 1716 cm⁻¹ respectively. The ¹H-NMR spectra showed peaks between 8.92-8.49, 8.25-6.93, and 4.95 -4.35 δ ppm for imidazole -CH, aromatic -CH, and -CH₂ protons respectively. The ²H-chromen-2-one proton of CH-8 and CH-15 appeared at 8.65 δ and 8.55 δ ppm respectively. The -OCH₃ protons appeared between 3.75 δ -3.74 δ ppm for CH-2, 8 and CH-13. The -CH₃ protons appeared at 2.29 δ ppm in CH-14. ¹³C-NMR spectra of CH-2 and CH-8 had shown peaks between 165-110 and 37 δ -36 δ ppm for aromatic and -CH₂ carbons respectively. The methyl carbons (-O-CH₃) of CH-2 and 8 appeared at 55 δ ppm. The mass spectra of CH-2 and CH-8 had shown molecular ion peaks in positive mode at m/z 340.02 and 390.08 respectively. The FTIR, ¹H-NMR, ¹³C-NMR and HRMS data were summarized.

Anticancer activity in human and murine tumor cell lines

All the compounds (CH-69 to CH-84) were evaluated for their cytostatic activity against human HeLa cervix carcinoma cells, human CEM CD4⁺ T-lymphocytes as well as murine L1210 cells. All assays were performed in 96-well microtiter plates. To each well were added (5-7.5) $\times 10^4$ tumor cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37°C in a humidified CO₂ controlled atmosphere. At the end of the incubation period, the cells were counted in a coulter counter. The IC₅₀ (50% inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50%.

Antiviral activity assays

The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain Kos, Thymidine Kinase-Deficient (TK-) HSV-1 Kos strain resistant to ACV (ACVr), Herpes Simplex Virus Type 2 (HSV-2) strains Lyons and G, Varicella Zoster Virus (VZV) strain Oka, TKVZV strain 07-1, Human Cytomegalovirus (HCMV) strains AD-169 and Davis, a clinical isolate of Adenovirus

type 2 (Ad2), Human Herpes Virus 6 subtype A (HHV-6A) strain GS, vaccinia virus Lederle strain, Respiratory Syncytial Virus (RSV) strain Long, Vesicular Stomatitis Virus (VSV), Coxsackie B4, parainfluenza 3, reovirus-1, Sindbis, Punta Toro, Yellow Fever Virus (YFV), human immunodeficiency virus type 1 strain IIB, human immunodeficiency virus type 2 strain ROD, and Hepatitis C Virus (HCV). The antiviral, other than anti-HIV and anti-HCV, assays were based on inhibition of virus-induced cytopathicity or plaque formation in Human Embryonic Lung (HEL) fibroblasts, African green monkey cells (Vero), Human Epithelial cells (HeLa), or Human T-lymphoblasts (HSB-2), according to previously established procedures. Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID₅₀ of virus (1 CCID₅₀ being the virus dose to infect 50% of the cell cultures) or with 20 Plaque-Forming Units (PFUs). After a 1 h-2 h adsorption period, residual virus was removed, and the cell cultures were incubated in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation (VZV) was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the EC₅₀, or the concentration required to reduce virus induced cytopathogenicity or viral plaque formation by 50%.

Cytotoxicity assays

Cytotoxicity measurements were based on the inhibition of cell growth. HEL cells were seeded at a rate of 5 cells-10³ cells/well into 96-well microtiter plates and allowed to proliferate for 24 h. Then, medium containing different concentrations of the test compounds was added. After 3 days of incubation at 37°C, the cell number was determined with a coulter counter. The cytostatic concentration was calculated as the CC₅₀, or the compound concentration required to reduce cell proliferation by 50% relative to the number of cells in the untreated controls. CC₅₀ values were estimated from graphic plots of the number of cells (percentage of control) as a function of the concentration of the test compounds. Alternatively, cytotoxicity for cell morphology was expressed as the Minimum Cytotoxic Concentration (MCC), or the compound concentration that caused a microscopically detectable alteration of cell morphology.

Inhibitory effects of compounds (CH-69 to CH-84) on the proliferation of murine leukemia cells (L1210) and human T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa) (Tables 7 and 8).

Compound	IC ₅₀ [*] (μM)		
	L1210	CEM	HeLa
CH-69	>250	>250	>250
CH-70	211 ± 14	138 ± 35	>250
CH-71	≥ 250	196 ± 4	>250
CH-72	>250	>250	>250
CH-73	>250	>250	>250
CH-74	>250	>250	>250
CH-75	>250	>250	>250
CH-76	>250	>250	>250
CH-77	≥ 250	165 ± 6	>250
CH-78	NT	NT	NT
CH-79	>250	>250	>250
CH-80	NT	NT	NT
CH-81	NT	NT	NT
CH-82	>250	>250	>250
CH-83	23 ± 1	3.5 ± 0.8	9.5 ± 0.4
CH-84	1.6 ± 0.4	0.77 ± 0.06	0.38 ± 0.03

^{*}50% inhibitory concentration.

Table 7. Inhibitory effects of compounds.

Compound	Cytotoxicity		Antiviral EC ₅₀ ^c		
	CC ₅₀ ^a	Minimum cytotoxic concentration ^b	Influenza A/H ₁ N ₁ A/Ned/378/05	Influenza A/H ₃ N ₂ A/HK/7/87	Influenza B B/Ned/537/05

			Visual score	CPE	MTS	Visual score	CPE	MTS	Visual score	CPE	MTS
CH-69	52.8	100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-70	>100	≥ 100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-71	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-72	>100	≥ 100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-73	>100	≥ 100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-74	>100	≥ 20	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-75	51.4	≥ 20	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-76	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-77	>100	20	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-78	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
CH-79	>100	>100	50	32.8	100	>100	20	11.7			
CH-80	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
CH-81	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
CH-82	>100	≥ 100	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-83	>100	≥ 20	>100	>100	>100	>100	>100	>100	>100	>100	>100
CH-84	2	≥ 0.8	>100	>100	>100	>100	>100	>100	>100	>100	>100
Zanamivir	>100	>100	0.3	0.05	4	11.6	0.09	0.07			
Ribavirin	>100	>100	20	4	20	9.1	6.8	3.1			
Amantadine	>200	>200	20	9.2	4	2.8	>200	>200			
Rimantadine	>200	>200	40	15.9	0.8	0.1	>200	>200			

Note: ^a50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.

^bMinimum compound concentration that causes a microscopically detectable alteration of normal cell morphology.

^c50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by visual scoring of the CPE, or by measuring the cell viability with the colorimetric formazan-based MTS assay.

MDCK cells: Madin Darby canine kidney cells

Data indicating antiviral activity are shown in red font, and marked in yellow if the SI (ratio of MCC to EC₅₀) is five or higher (Tables 9-12).

Note that the SI can not be accurately calculated for compounds showing no cytotoxicity at the highest concentration tested (100 μM).

Table 8. Cytotoxicity and antiviral activity in: MDCK cell cultures (μM).

EC ₅₀ ^b							
Compound	Minimum cytotoxic concentration ^a	Herpes simplex virus-1 (KOS)	Herpes simplex virus-2 (G)	Herpes simplex virus-1 TK-KOS ACV ^c	Vaccinia virus	Adeno virus-2	Human Coronavirus (229E)
CH-69	>100	>100	>100	>100	>100	>100	>100
CH-70	>100	>100	>100	>100	>100	>100	>100
CH-71	100	>100	>100	>100	>100	>100	>100
CH-72	>100	>100	>100	>100	>100	>100	>100
CH-73	>100	>100	>100	>100	>100	>100	>100
CH-74	>100	>100	>100	>100	>100	>100	>100
CH-75	>100	>100	>100	>100	>100	>100	>100

CH-76	>100	>100	>100	>100	>100	>100	>100
CH-77	>100	>100	>100	>100	>100	>100	>100
CH-78	NT	NT	NT	NT	NT	NT	NT
CH-79	20	>100	>100	>100	>100	>100	>100
CH-80	NT	NT	NT	NT	NT	NT	NT
CH-81	NT	NT	NT	NT	NT	NT	NT
CH-82	100	>100	>100	>100	>100	>100	>100
CH-83	100	>100	>100	>100	>100	>100	>100
CH-84	20	>100	>100	>100	>100	>100	>100
Brivudin	>250	0.08	112	>250	10	-	-
Cidofovir	>250	5	2	2	14	10	-
Acyclovir	>250	0.08	0.8	>250	>250	-	-
Ganciclovir	>100	0.3	0.094	20	>100	-	-
Zalcitabine	>250	-	-	-	-	5.8	-
Alovudine	>250	-	-	-	-	10	-
UDA	>100	-	-	-	-	-	1.8
Ribavirin	>250	-	-	-	-	-	85

Note: ^aRequired to cause a microscopically detectable alteration of normal cell morphology; ^bRequired to reduce virus-induced cytopathogenicity by 50%.

Table 9. Cytotoxicity and antiviral activity in: HEL cell cultures (Concentration μM).

EC50 ^b								
Compound	Concentration unit	Minimum concentration ^a	cytotoxic	Vesicular virus	stomatitis	Coxsackie virus B4	Respiratory	syncytial virus
69	μM	>100		>100		>100	>100	
70	μM	>100		>100		>100	>100	
71	μM	>100		>100		>100	>100	
72	μM	>100		>100		>100	>100	
73	μM	>100		>100		>100	>100	
74	μM	100		>100		>100	>100	
75	μM	>100		>100		>100	>100	
76	μM	>100		>100		>100	>100	
77	μM	100		>100		>100	>100	
78	--	NT		NT		NT	NT	
79	μM	≥ 100		>100		>100	>100	
80	--	NT		NT		NT	NT	
81	--	NT		NT		NT	NT	
82	μM	>100		>100		>100	>100	
83	μM	100		>100		>100	>100	
84	μM	4		>100		>100	>100	

DS-10.000	µg/ml	>100	1.4	>100	0.5
Ribavirin	µM	>250	5	146	3.4

Note: ^aRequired to cause a microscopically detectable alteration of normal cell morphology; ^bRequired to reduce virus-induced cytopathogenicity by 50%.

Table 10. Cytotoxicity and antiviral activity in: HeLa cell cultures.

EC50 ^b									
Compound	Concentration unit	Minimum cytotoxic concentration ^a	Para-influenza-3 virus	Reovirus-1	Sindbis virus	Coxsackie virus B4	Punta Toro virus	Yellow Fever virus	
CH-69	µM	≥ 20	>100	>100	>100	>100	>100	>100	
CH-70	µM	>100	>100	>100	>100	>100	>100	>100	
CH-71	µM	100	>100	>100	>100	>100	>100	>100	
CH-72	µM	>100	>100	>100	>100	>100	>100	>100	
CH-73	µM	>100	>100	>100	>100	>100	>100	>100	
CH-74	µM	≥ 20	>100	>100	>100	>100	>100	>100	
CH-75	µM	100	>100	>100	>100	>100	>100	>100	
CH-76	µM	>100	>100	>100	>100	>100	>100	>100	
CH-77	µM	≥ 20	>100	>100	>100	>100	>100	>100	
CH-78	–	NT	NT	NT	NT	NT	NT	NT	
CH-79	µM	100	>100	>100	>100	>100	>100	>100	
CH-80	–	NT	NT	NT	NT	NT	NT	NT	
CH-81	–	NT	NT	NT	NT	NT	NT	NT	
CH-82	µM	>100	>100	>100	>100	>100	>100	>100	
CH-83	µM	100	>100	>100	>100	>100	>100	>100	
CH-84	µM	≥ 0.8	>100	>100	>100	>100	>100	>100	
DS-10.000	µg/ml	>100	>100	>100	>100	58	50	0.4	
Ribavirin	µM	≥ 250	19	111	>250	>250	25	>250	
Mycophenolic acid	µM	>100	0.4	0.6	>100	>250	2.3	0.8	

Note: ^aRequired to cause a microscopically detectable alteration of normal cell morphology; ^bRequired to reduce virus-induced cytopathogenicity by 50%.

Table 11. Cytotoxicity and antiviral activity in: Vero cell cultures.

EC50 ^b				
Compound	Concentration unit	CC ₅₀ ^a	Feline Corona Virus (FIPV)	Feline Herpes Virus
CH-69	µM	>100	>100	>100
CH-70	µM	>100	>100	>100
CH-71	µM	>100	>100	>100
CH-72	µM	>100	>100	>100
CH-73	µM	>100	>100	>100
CH-74	µM	>100	>100	>100

CH-75	μM	>100	>100	>100
CH-76	μM	>100	>100	>100
CH-77	μM	13	>100	>100
CH-78	--	NT	NT	NT
CH-79	μM	39.6	>100	>100
CH-80	--	NT	NT	NT
CH-81	--	NT	NT	NT
CH-82	μM	>100	>100	>100
CH-83	μM	>100	>100	>100
CH-84	μM	4.9	>100	>100
HHA	μg/ml	>100	3.3	2.7
UDA	μg/ml	>100	14.4	9.1
Ganciclovir	μM	>100	>100	1.6

Note: ^a50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay; ^b50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.

CRFK cells: Crandell-Rees Feline Kidney cells.

Table 12. Cytotoxicity and antiviral activity in: CRFK cell cultures.

Reference

1. Sujeet K, Mahesh H, Vidya Gopalakrishnan and Vinaya Kumar R, et al. "2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4] Thiadiazoles: Synthesis, Cytotoxic Activity and Mechanism of Action." *Eur J Med Chem* 84 (2014): 687-697.
2. de Clercq E, Descamps J, Verhelst G and Walker RT, et al. "Comparative Efficacy of Antihpes Drugs Against Different Strains of Herpes Simplex Virus." *J Infect Dis* 141 (1980): 563-574.
3. de Clercq E, Sakuma T, Baba M and Pauwels R et al. "Antiviral Activity of Phosphonomethoxyalkyl Derivatives of Purine And Pyrimidines." *AntiViral Res* 8 (1987): 261-272.
4. de Bolle L, Michel D, Mertens T and Manichanh C, et al. "Role of the Human Herpesvirus 6 u69-encoded Kinase in the Phosphorylation of Ganciclovir." *Mol Pharmacol* 62 (2002): 714-721.
5. Kumar S, Gopalakrishnan V, Hegde M and Rana V, et al. "Synthesis and Antiproliferative Activity of Imidazo[2,1-b][1,3,4] Thiadiazole Derivatives." *Bioorganic Med Chem Lett* 24 (2014): 4682-88.
6. Kumar S, Hegde M, Gopalakrishnan V and Renuka VR, et al. "2-(4-Chlorobenzyl)-6-Arylimidazo[2,1-b][1,3,4]Thiadiazoles: Synthesis, Cytotoxic Activity and Mechanism of Action" *Eur J Med Chem* 84 (2014): 687-97.
7. Hegde M, Karki SS, Thomas E and Kumar S, et al. "Novel Levamisole Derivative Induces Extrinsic Pathway of Apoptosis in Cancer Cells and Inhibits Tumor Progression in Mice." *PLoS ONE* 7 (2012): 43632.
8. Karki SS, Panjamurthy K, Kumar S and Nambiar M, et al. "Synthesis And Biological Evaluation of Novel 2-Aralkyl-5-Substituted-6-(4'-Fluorophenyl)-Imidazo[2,1-B][1,3,4]Thiadiazole Derivatives As Potent Anticancer Agents." *Eur J Med Chem* 46 (2011): 2109-16.

How to cite this article: Sujith, Chudamani B and Subhas S Karki. "Synthesis of Novel Levamisole Derivatives for Their Anticancer and Antiviral Activity." *Chem Sci J* 13 (2022): 304.